Therapeutic Potential of Lactobacillus Casei and Chlorella Vulgaris in High-fat Diet-induced Non-alcoholic Fatty Liver Disease (NAFLD)-associated Kidney Damages: a Stereological Study

Overview

Journal Mol Biol Rep

Specialty Molecular Biology

Date 2024 May 5

PMID 38704764

Authors

Haniyeh Keyghobadi

Hadis Bozorgpoursavadjani

Farhad Koohpeyma

Nazanin Mohammadipoor

Marzieh Nemati

Farshad Dehghani

Iman Jamhiri

Gholamhossein Keighobadi

Sanaz Dastghaib

Affiliations

Soon will be listed here.

Abstract

Background: The non-alcoholic fatty liver disease (NAFLD) is prevalent in as many as 25% of adults who are afflicted with metabolic syndrome. Oxidative stress plays a significant role in the pathophysiology of hepatic and renal injury associated with NAFLD. Therefore, probiotics such as Lactobacillus casei (LBC) and the microalga Chlorella vulgaris (CV) may be beneficial in alleviating kidney injury related to NAFLD.

Materials And Methods: This animal study utilized 30 C57BL/6 mice, which were evenly distributed into five groups: the control group, the NAFLD group, the NAFLD + CV group, the NAFLD + LBC group, and the NAFLD + CV + LBC group. A high-fat diet (HFD) was administered to induce NAFLD for six weeks. The treatments with CV and LBC were continued for an additional 35 days. Biochemical parameters, total antioxidant capacity (TAC), and the expression of kidney damage marker genes (KIM 1 and NGAL) in serum and kidney tissue were determined, respectively. A stereological analysis was conducted to observe the structural changes in kidney tissues.

Results: A liver histopathological examination confirmed the successful induction of NAFLD. Biochemical investigations revealed that the NAFLD group exhibited increased ALT and AST levels, significantly reduced in the therapy groups (p < 0.001). The gene expression levels of KIM-1 and NGAL were elevated in NAFLD but were significantly reduced by CV and LBC therapies (p < 0.001). Stereological examinations revealed reduced kidney size, volume, and tissue composition in the NAFLD group, with significant improvements observed in the treated groups (p < 0.001).

Conclusion: This study highlights the potential therapeutic efficacy of C. vulgaris and L. casei in mitigating kidney damage caused by NAFLD. These findings provide valuable insights for developing novel treatment approaches for managing NAFLD and its associated complications.

References

Choi J, Joe H, Oh J, Cho Y, Shin H, Heo N . The correlation between NAFLD and serum uric acid to serum creatinine ratio. PLoS One. 2023; 18(7):e0288666. PMC: 10353803. DOI: 10.1371/journal.pone.0288666. View

Zheng X, Cao C, He Y, Wang X, Wu J, Hu H . Association between nonalcoholic fatty liver disease and incident diabetes mellitus among Japanese: a retrospective cohort study using propensity score matching. Lipids Health Dis. 2021; 20(1):59. PMC: 8207755. DOI: 10.1186/s12944-021-01485-x. View

Mantovani A, Lombardi R, Cattazzo F, Zusi C, Cappelli D, Dalbeni A . MAFLD and CKD: An Updated Narrative Review. Int J Mol Sci. 2022; 23(13). PMC: 9266672. DOI: 10.3390/ijms23137007. View

Lonardo A, Mantovani A, Targher G, Baffy G . Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease: Epidemiology, Pathogenesis, and Clinical and Research Implications. Int J Mol Sci. 2022; 23(21). PMC: 9654863. DOI: 10.3390/ijms232113320. View

Hydes T, Buchanan R, Kennedy O, Fraser S, Parkes J, Roderick P . Systematic review of the impact of non-alcoholic fatty liver disease on mortality and adverse clinical outcomes for individuals with chronic kidney disease. BMJ Open. 2020; 10(9):e040970. PMC: 7523199. DOI: 10.1136/bmjopen-2020-040970. View

Chen L, Lv X, Kan M, Wang R, Wang H, Zang H . Critical Overview of Hepatic Factors That Link Non-Alcoholic Fatty Liver Disease and Acute Kidney Injury: Physiology and Therapeutic Implications. Int J Mol Sci. 2022; 23(20). PMC: 9604121. DOI: 10.3390/ijms232012464. View

Francoz C, Nadim M, Durand F . Kidney biomarkers in cirrhosis. J Hepatol. 2016; 65(4):809-824. DOI: 10.1016/j.jhep.2016.05.025. View

Lee N, Shin M, Youn G, Yoon S, Choi Y, Kim H . Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis. Clin Mol Hepatol. 2020; 27(1):110-124. PMC: 7820205. DOI: 10.3350/cmh.2020.0125. View

Machu L, Misurcova L, Ambrozova J, Orsavova J, Mlcek J, Sochor J . Phenolic content and antioxidant capacity in algal food products. Molecules. 2015; 20(1):1118-33. PMC: 6272319. DOI: 10.3390/molecules20011118. View

10.

Wan M, Li Q, Lei Q, Zhou D, Wang S . Polyphenols and Polysaccharides from L. Fruit Attenuate High-Fat Diet-Induced Metabolic Syndrome Modifying the Gut Microbiota and Metabolite Profile. Foods. 2022; 11(12). PMC: 9223293. DOI: 10.3390/foods11121818. View

11.

Panahi Y, Ghamarchehreh M, Beiraghdar F, Zare R, Jalalian H, Sahebkar A . Investigation of the effects of Chlorella vulgaris supplementation in patients with non-alcoholic fatty liver disease: a randomized clinical trial. Hepatogastroenterology. 2012; 59(119):2099-2103. DOI: 10.5754/hge10860. View

12.

Mohseni R, Alavian S, Sadeghabadi Z, Heiat M . Therapeutic effects of Chlorella vulgaris on carbon tetrachloride induced liver fibrosis by targeting Hippo signaling pathway and AMPK/FOXO1 axis. Mol Biol Rep. 2020; 48(1):117-126. DOI: 10.1007/s11033-020-05978-3. View

13.

Zhang Z, Zhou H, Guan M, Zhou X, Liang X, Lv Y . YRL577 combined with plant extracts reduce markers of non-alcoholic fatty liver disease in mice. Br J Nutr. 2020; 125(10):1081-1091. DOI: 10.1017/S0007114520003013. View

14.

Zhang Z, Zhou H, Zhou X, Sun J, Liang X, Lv Y . YRL577 ameliorates markers of non-alcoholic fatty liver and alters expression of genes within the intestinal bile acid pathway. Br J Nutr. 2020; 125(5):521-529. DOI: 10.1017/S0007114520003001. View

15.

SCHERLE W . A simple method for volumetry of organs in quantitative stereology. Mikroskopie. 1970; 26(1):57-60. View

16.

Roderburg C, Krieg S, Krieg A, Demir M, Luedde T, Kostev K . Non-alcoholic fatty liver disease (NAFLD) is associated with an increased incidence of chronic kidney disease (CKD). Eur J Med Res. 2023; 28(1):153. PMC: 10108448. DOI: 10.1186/s40001-023-01114-6. View

17.

Regueiras A, Huguet A, Conde T, Couto D, Domingues P, Domingues M . Potential Anti-Obesity, Anti-Steatosis, and Anti-Inflammatory Properties of Extracts from the Microalgae and under Different Growth Conditions. Mar Drugs. 2022; 20(1). PMC: 8781425. DOI: 10.3390/md20010009. View

18.

Imamura Y, Mawatari S, Oda K, Kumagai K, Hiramine Y, Saishoji A . Changes in body composition and low blood urea nitrogen level related to an increase in the prevalence of fatty liver over 20 years: A cross-sectional study. Hepatol Res. 2021; 51(5):570-579. DOI: 10.1111/hepr.13631. View

19.

Aron-Wisnewsky J, Warmbrunn M, Nieuwdorp M, Clement K . Nonalcoholic Fatty Liver Disease: Modulating Gut Microbiota to Improve Severity?. Gastroenterology. 2020; 158(7):1881-1898. DOI: 10.1053/j.gastro.2020.01.049. View

21.

Yang M, Geng C, Liu X, Guan M . Lipid Disorders in NAFLD and Chronic Kidney Disease. Biomedicines. 2021; 9(10). PMC: 8533451. DOI: 10.3390/biomedicines9101405. View